Leadiant Biosciences, Inc. is recalling 3,398 bottles of Cystaran (cysteamine ophthalmic solution) 0.44% because the medication was found to be subpotent. This means the drug does not contain the required amount of the active ingredient, cysteamine hydrochloride, to be fully effective. The affected 15 mL bottles were distributed through Walgreens Specialty Pharmacy in Pittsburgh and internationally to Italy and Germany.
If the medication is subpotent, patients may not receive the full therapeutic dose intended by their doctor. This could result in the treatment being less effective or failing to manage the condition as expected.
Pharmacy refund and healthcare consultation
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES ยท Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.